Strides Arcolab Ltd (Strides) profits are lower by 10.55 per cent to Rs 61.19 crore on a consolidated basis for the fourth quarter (Q4) this fiscal.
The company’s revenues fell by 7.86 per cent to Rs 633.10 crore in the same quarter, while EPS stood at Rs 10.41 against Rs 11.79 for the last year.
“Last year has been a satisfying year magnified by operating leverage in both Agila and Pharma businesses with continued compliances across all manufacturing facilities globally and a profound regulatory filing programme,” said Arun Kumar, Vice-Chairman & Group CEO.
Regulatory filings
Strides has filed 25 filings in the US market in the fourth quarter (till date 257 filings), company got five approvals in the quarter (till date 107), tentative approvals/PEPFAR nil for the quarter (till date 22), available for commercialisation 5l (till date 85) and products commercialised seven in the quarter (till date 57).
Agila Specialities
Total revenues at Rs 365 crore (Rs 285 crore in Q4’11), with EBITDA of Rs 115 crore (Rs 70 crore in Q4’11).
Operational revenues excluding Brazil at Rs 236 crore (Rs 70 crore in Q4’11), up by 237 per cent with EBITDA margin of 45 per cent (above guidance range of 23 per cent to 30 per cent).
Licensing revenues of Rs 58 crore in Q4’12 (Rs 163 crore in Q4’11).
Pharma division
Total revenues excluding divested Ascent Australasian Operations at Rs 284 crore (Rs 178 crore in Q4’11), with EBITDA of Rs 28 crore (Rs 14 crore in Q4’11).
Operational revenues excluding Ascent Operations grew by 58 per cent to Rs 271 crore (Rs 172 crore in Q4’11) with EBITDA margin at 18 per cent.
Licencing revenues of Rs 13 crore in Q4’12 (Rs 6 crore in Q4’11) and licencing revenues impacted by Rs 19 crore as the company bought back key range of immuno-suppressants which the company expects to launch on its own in Q2’13.
anil.u@thehindu.co.in